ZOMETA in Advanced Cancers

For non-US healthcare professionals: Get information about ZOMETA and its product characteristics.

Tumour-Induced Hypercalcaemia (TIH)

This is an international site for Zometa^® (zoledronic acid) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Zometa Information for US residents Zometa Information for Patients Outside the US

Welcome to the ZOMETA Product Website

ZOMETA is approved for use in
95 countries
around the world.

ZOMETA Country-Level Websites

Below is a list of the countries that host a ZOMETA website based on local label and in local language. They are intended for Healthcare Professional (HCPs) only. Click on any of the links to be redirected to that country-level website.

ZOMETA International Website

This website is intended for Healthcare Professionals (HCPs) outside the U.S. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus .

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC)

Text size:

Treat TIH with ZOMETA¹

ZOMETA delivers superior efficacy vs pamidronate in the treatment of TIH²

ZOMETA decreases serum calcium and urinary calcium excretion in patients with tumour-induced hypercalcaemia¹
Significantly more patients had a complete response with ZOMETA than with pamidronate at 7 and 10 days after treatment²
At 10 days, the complete response rate was 88% for ZOMETA vs 70% for pamidronate (P=0.002)²

Learn about ZOMETA dosing in patients with TIH.

References: 1. ZOMETA Summary of Product Characteristics. Novartis Pharma AG. 2. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19:558-567.